已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

The use of advanced machine learning to predict outcomes after atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: a retrospective cohort study

阿替唑单抗 医学 贝伐单抗 回顾性队列研究 肿瘤科 内科学 机器学习 人工智能 队列研究 队列 梅德林 临床试验 外科
作者
Mathew Vithayathil,Giulia Francesca Manfredi,Antonio D’Alessio,Claudia Angela Maria Fulgenzi,Ciro Celsa,Pasquale Lombardi,Aria Torkpour,Bernardo Stefanini,Peter R Galle,Naoshi Nishida,B Scheiner,Fionnuala Crowley,Linda Wu,Celina Ang,Thomas U Marron,Wei-Fan Hsu,Chun-Yen Lin,Ryan Po-Ting Lin,Susanna V. Ulahannan,Haripriya Andanamala
出处
期刊:The Lancet Digital Health [Elsevier BV]
卷期号:8 (2): 100952-100952 被引量:1
标识
DOI:10.1016/j.landig.2025.100952
摘要

BACKGROUND: Combination immune checkpoint inhibitors are recommended as first-line therapy for advanced hepatocellular carcinoma. However, only a third of patients respond to treatment, and improved approaches to predict response are required. Using baseline clinical data, we aimed to use advanced machine learning models to predict overall survival and progression-free survival in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab. METHODS: This retrospective cohort study was conducted at 24 centres across eight countries. Patients aged 18 years and older with a histological or radiological diagnosis of advanced hepatocellular carcinoma were included; those who had received previous systemic therapy for hepatocellular carcinoma were excluded. All patients received intravenous atezolizumab 1200 mg plus bevacizumab 15 mg/kg once every 3 weeks until disease progression. Seven supervised machine learning models, in combination with 13 feature selection techniques, were trained on 44 baseline clinical variables for the prediction of overall survival and progression-free survival. The three best-performing models, combined with their optimum feature selection techniques, were used to develop ensemble machine learning models for the prediction of overall survival and progression-free survival. The primary outcomes of the study were the predictions of overall survival, progression-free survival, and immunotherapy response using advanced machine learning. k-means clustering was used to stratify patients into two groups: those at low risk and those at high risk of either death (in the overall survival model) or disease progression (in the progression-free survival model). FINDINGS: 934 patients who received immunotherapy from May 1, 2018 and were followed up until Oct 1, 2023 were screened, of whom 160 were excluded and 774 were included in the final study. Patients were divided into training (n=339), internal validation (n=146) and external validation (n=289) cohorts. Support vector machine, neural network, and naive Bayes algorithms had the best performance in the prediction of overall survival; for progression-free survival, the highest-performing algorithms were ridge regression, naive Bayes, and logistic regression. In the external validation cohort, the ensemble model for the prediction of overall survival (area under the receiver operating characteristic curve 0·75 [95% CI 0·69-0·81]) significantly outperformed all eight of the tested clinical benchmark variables: Barcelona Clinic Liver Cancer (BCLC) stage (0·54 [0·48-0·61]; p<0·0001), α-fetoprotein (AFP) concentration (0·60 [0·54-0·67]; p=0·0007), albumin-bilirubin (ALBI) grade (0·64 [0·58-0·71]; p=0·0003), neutrophil-to-lymphocyte ratio (0·56 [0·49-0·62]; p<0·0001), platelet-to-lymphocyte ratio (0·51 [0·44-0·58]; p<0·0001), combined ALBI grade and BCLC stage (0·67 [0·60-0·73]; p=0·0074), and two BCLC subclassifications (0·62 [0·55-0·69]; p=0·0007 and 0·61 [0·55-0·68]; p=0·0018). The ensemble model for the prediction of progression-free survival (0·64 [0·59-0·70]) outperformed five of the eight clinical predictors: BCLC stage (0·52 [0·46-0·58]; p<0·0001), neutrophil-to-lymphocyte ratio (0·53 [0·47-0·59]; p=0·0069), platelet-to-lymphocyte ratio (0·54 [0·48-0·60]; p=0·016), and two BCLC subclassifications (0·57 [0·50-0·64]; p=0·020 and 0·55 [0·49-0·62]; p=0·0091); the model did not outperform AFP concentration (0·59 [0·53-0·64]; p=0·14), ALBI grade (0·62 [0·56-0·67]; p=0·44), or combined ALBI grade and BCLC stage (0·59 [0·53-0·66]; p=0·12). For the overall survival model, patients stratified into the low-risk group had significantly longer median overall survival (16·4 months [95% CI 14·2-21·6]) than those in the high-risk group (4·8 months [3·0-6·9]; p<0·0001); similarly, patients stratified by the progression-free survival model into the low-risk group had significantly longer median progression-free survival (8·9 months [7·3-11·1]) than those in the high-risk group (3·7 months [2·9-5·6]; p=0·0021). INTERPRETATION: Our advanced machine learning models, which use routinely collected baseline clinical variables, are robust and externally validated and outperform established clinical biomarkers for predicting clinical outcomes with atezolizumab plus bevacizumab. These data-driven models could be used to stratify patients with hepatocellular carcinoma for personalised treatment strategies. FUNDING: None.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
4rcanist完成签到,获得积分10
刚刚
海棠拾月完成签到 ,获得积分10
刚刚
上官若男的应助被Dtt采纳,获得10
1秒前
2秒前
u511277发布了新的文献求助10
2秒前
和信完成签到 ,获得积分10
3秒前
3秒前
刘kk完成签到 ,获得积分10
3秒前
4秒前
4秒前
Assam完成签到,获得积分10
4秒前
英姑的应助被传统的成败采纳,获得10
5秒前
u511277发布了新的文献求助10
5秒前
海流完成签到 ,获得积分10
6秒前
6秒前
沐雨完成签到,获得积分10
6秒前
aaaq发布了新的文献求助10
6秒前
7秒前
8秒前
huyu完成签到 ,获得积分10
9秒前
10秒前
90min完成签到 ,获得积分10
11秒前
11秒前
鲤鱼烧鹅发布了新的文献求助10
11秒前
11秒前
Dtt完成签到,获得积分10
12秒前
传统的成败完成签到,获得积分10
12秒前
落寞代灵完成签到 ,获得积分10
12秒前
Allen0520完成签到,获得积分10
12秒前
小橙子完成签到,获得积分10
12秒前
13秒前
水星发布了新的文献求助10
13秒前
传奇3的应助被小柴胡采纳,获得10
15秒前
UU有点皮完成签到 ,获得积分10
15秒前
15秒前
PANDA发布了新的文献求助10
16秒前
17秒前
大模型的应助被Wendy0911采纳,获得10
17秒前
wangli完成签到,获得积分10
18秒前
上官若男的应助被ZJ采纳,获得10
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8194810
求助须知:如何正确求助?哪些是违规求助? 9580544
关于积分的说明 21871741
捐赠科研通 7794414
什么是DOI,文献DOI怎么找? 3437768
关于科研通互助平台的介绍 2561095
邀请新用户注册赠送积分活动 2484480